相关实验视频

Updated: Jun 27, 2025

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

具有抗超血性活性的食物衍生生物活性:综合性审查

Arshad Mehmood¹, Asra Iftikhar², Xiumin Chen³

¹School of Food and Biological Engineering, Jiangsu University, 301 Xuefu Road, Jingkou District, Zhenjiang, Jiangsu 212013, PR China; Institute of Food Physical Processing, Jiangsu University, 301 Xuefu Road, Jingkou District, Zhenjiang, Jiangsu 212013, PR China.

|April 28, 2024

概括

来自食物的生物活性 (FBPs) 通过降低尿酸 (UA) 水平来管理高尿血症 (HU). 这些天然化合物为传统药物提供了更安全的替代品,因为它们针对涉及HU的多种机制.

科学领域:

生物化学生化学
营养科学营养科学
药理学药理学是指药理学的学科.

背景情况:

超尿血症 (HU) 是一种与尿酸 (UA) 水平升高相关的代谢障碍.
目前用于HU的全方位治疗通常会导致不良副作用.
对安全有效的抗高尿路血症疗法有显著的需求.

研究的目的:

审查食品衍生生物活性 (FBPs) 的尿酸降低潜力.
阐明FBP缓解高尿血的潜在机制.
探索FBP作为管理HU的功能成分.

主要方法:

对研究FBP及其对尿酸代谢的影响的文献综述.
分析包括酶抑制,分泌和再吸收在内的机制.
对抗氧化,抗炎和肠道微生物群调节效应的评估.

主要成果:

FBPs有效地降低了血液中的UA水平.
机制包括抑制桑丁氧化酶,增强脏UA分泌,减少脏UA再吸收.
此外,FBP还显示出抗氧化活性增加,对炎症媒介的调节,以及对肠道微生物群的积极调节.

结论:

食品衍生的生物活性 (FBPs) 显示出显著的潜力,以改善高尿路血.
FBPs通过各种生理途径为管理HU提供了多方面的方法.
对FBP的进一步研究可能会导致针对高尿血的新自然治疗策略.

关键词:

生物活性酸是一种生物活性酸.这是一种痛风,痛风.我们的肠道微生物群.超性血症 (hyperuricemia) 是一种疾病,尿酸是什么尿酸是什么

更多相关视频

Separation of Bioactive Small Molecules, Peptides from Natural Sources and Proteins from Microbes by Preparative Isoelectric Focusing IEF Method

Separation of Bioactive Small Molecules, Peptides from Natural Sources and Proteins from Microbes by Preparative Isoelectric Focusing IEF Method

Published on: June 14, 2020

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...